| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5006528 | OTSUKA | Carbostyril derivatives |
Oct, 2014
(9 years ago) | |
| US9359302 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 6 months ago) | |
| US8642760 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 6 months ago) | |
| US8580796 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Sep, 2022
(1 year, 6 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5006528 (Pediatric) | OTSUKA | Carbostyril derivatives |
Apr, 2015
(9 years ago) | |
| US9358207 | OTSUKA | Flashmelt oral dosage formulation |
Apr, 2020
(4 years ago) | |
| US8518421 | OTSUKA | Flashmelt oral dosage formulation |
Jan, 2021
(3 years ago) | |
|
US8518421 (Pediatric) | OTSUKA | Flashmelt oral dosage formulation |
Jul, 2021
(2 years ago) | |
| US9089567 | OTSUKA | Method of treating cognitive impairments and schizophrenias |
Jan, 2022
(2 years ago) | |
| US7053092 | OTSUKA | 5-HT1a receptor subtype agonist |
Jan, 2022
(2 years ago) | |
| US8642600 | OTSUKA | Method of treating autism |
Jan, 2022
(2 years ago) | |
| US6977257 | OTSUKA | Aripiprazole oral solution |
Apr, 2022
(1 year, 11 months ago) | |
|
US8642600 (Pediatric) | OTSUKA | Method of treating autism |
Jul, 2022
(1 year, 8 months ago) | |
|
US6977257 (Pediatric) | OTSUKA | Aripiprazole oral solution |
Oct, 2022
(1 year, 5 months ago) | |
|
US8642760 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(1 year, 26 days ago) | |
|
US8580796 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Mar, 2023
(1 year, 26 days ago) | |
| US9387182 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Dec, 2023
(3 months ago) | |
| US8017615 | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Jun, 2024
(a month from now) | |
| US7115587 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(3 months from now) | |
| US7550445 | OTSUKA | Aripiprazole complex formulation and method |
Jul, 2024
(3 months from now) | |
|
US8017615 (Pediatric) | OTSUKA | Low hygroscopic aripiprazole drug substance and processes for the preparation thereof |
Dec, 2024
(7 months from now) | |
|
US7550445 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(9 months from now) | |
|
US7115587 (Pediatric) | OTSUKA | Aripiprazole complex formulation and method |
Jan, 2025
(9 months from now) | |
| US9125939 | OTSUKA | Carbostyril derivatives and mood stabilizers for treating mood disorders |
Jul, 2026
(2 years from now) | |
| US8759350 | OTSUKA | Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders |
Mar, 2027
(2 years from now) | |
Abilify is owned by Otsuka.
Abilify contains Aripiprazole.
Abilify has a total of 25 drug patents out of which 17 drug patents have expired.
Expired drug patents of Abilify are:
- US5006528*PED
- US9358207
- US8518421
- US8518421*PED
- US9089567
- US7053092
- US8642600
- US6977257
- US8642600*PED
- US6977257*PED
- US8642760*PED
- US8580796*PED
- US9387182
- US5006528
- US9359302
- US8642760
- US8580796
Abilify was authorised for market use on 15 November, 2002.
Abilify is available in tablet, orally disintegrating;oral, tablet;oral, solution;oral, injectable;intramuscular dosage forms.
Abilify can be used as adjunctive treatment of major depressive disorder (mdd), treatment of irritability associated with autistic disorder, treatment of schizophrenia, treatment of schizophrenia including maintaining stability in patients with schizophrenia, treatment of schizophrenia, acute treatment of manic and mixed episodes associated with bipolar i disorder, adjunctive treatment of major depressive disorder, and treatment of irritability associated with autistic disorder, treatment of major depressive disorder (mdd), acute treatment of manic and mixed episodes associated with bipolar i disorder.
The generics of Abilify are possible to be released after 02 March, 2027.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Aug 27, 2011 |
| Orphan Drug Exclusivity(ODE) | Dec 12, 2021 |
| M(M-137) | Jun 09, 2017 |
| New Indication(I-700) | Dec 12, 2017 |
| Orphan Drug Exclusivity(ODE-80) | Dec 12, 2021 |
| New Indication(I-633) | Feb 16, 2014 |
| New Indication(I-616) | Nov 19, 2012 |
Drugs and Companies using ARIPIPRAZOLE ingredient
Market Authorisation Date: 15 November, 2002
Treatment: Treatment of schizophrenia; Treatment of major depressive disorder (mdd); Treatment of irritability associated with autistic disorder; Adjunctive treatment of major depressive disorder (mdd); Acute tr...
Dosage: TABLET;ORAL; INJECTABLE;INTRAMUSCULAR; SOLUTION;ORAL; TABLET, ORALLY DISINTEGRATING;ORAL
ABILIFY family patents
